Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Osiyemi

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Open Forum Infectious Diseases|December 29, 2025
Subcutaneous Lenacapavir in People With Multidrug-Resistant HIV-1: 156 Week Results of the CAPELLA StudyOnyema Ogbuagu, Andrew Wiznia, Joseph P McGowan, et al.
Infectious Diseases and Therapy|September 15, 2025
The Effects of Cobicistat and Voriconazole on the Safety, Pharmacokinetics, and Pharmacodynamics of the TLR7 Agonist Vesatolimod in People with HIVYanan Zheng, Mary Wire, Robert Were Omange, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 26, 2022
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized TrialOlayemi Osiyemi, Stéphane De Wit, Faïza Ajana, et al.
The Lancet. HIV|May 11, 2024
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trialAnthony M Mills, Giuliano Rizzardini, Moti N Ramgopal, et al.
HIV Medicine|August 14, 2018
Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trialsD Hagins, C Orkin, E S Daar, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 7, 2020
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO StudyJean van Wyk, Faïza Ajana, Fiona Bisshop, et al.
Antiviral Therapy|July 30, 2019
Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trialJose M Gatell, Javier O Morales-Ramirez, Debbie P Hagins, et al.
Lancet (London, England)|February 7, 2026
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trialAmy E Colson, Anthony M Mills, Moti N Ramgopal, et al.
The Lancet. HIV|August 11, 2023
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trialMoti N Ramgopal, Antonella Castagna, Charles Cazanave, et al.
The New England Journal of Medicine|December 22, 2021
Early Remdesivir to Prevent Progression to Severe Covid-19 in OutpatientsRobert L Gottlieb, Carlos E Vaca, Roger Paredes, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Open Forum Infectious Diseases|December 29, 2025
Subcutaneous Lenacapavir in People With Multidrug-Resistant HIV-1: 156 Week Results of the CAPELLA StudyOnyema Ogbuagu, Andrew Wiznia, Joseph P McGowan, et al.
Infectious Diseases and Therapy|September 15, 2025
The Effects of Cobicistat and Voriconazole on the Safety, Pharmacokinetics, and Pharmacodynamics of the TLR7 Agonist Vesatolimod in People with HIVYanan Zheng, Mary Wire, Robert Were Omange, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 26, 2022
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized TrialOlayemi Osiyemi, Stéphane De Wit, Faïza Ajana, et al.
The Lancet. HIV|May 11, 2024
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trialAnthony M Mills, Giuliano Rizzardini, Moti N Ramgopal, et al.
HIV Medicine|August 14, 2018
Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trialsD Hagins, C Orkin, E S Daar, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 7, 2020
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO StudyJean van Wyk, Faïza Ajana, Fiona Bisshop, et al.
Antiviral Therapy|July 30, 2019
Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trialJose M Gatell, Javier O Morales-Ramirez, Debbie P Hagins, et al.
Lancet (London, England)|February 7, 2026
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trialAmy E Colson, Anthony M Mills, Moti N Ramgopal, et al.
The Lancet. HIV|August 11, 2023
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trialMoti N Ramgopal, Antonella Castagna, Charles Cazanave, et al.
The New England Journal of Medicine|December 22, 2021
Early Remdesivir to Prevent Progression to Severe Covid-19 in OutpatientsRobert L Gottlieb, Carlos E Vaca, Roger Paredes, et al.
Pageof 6